Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Rituximab 117Cyclophosphamide 104fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Cytarabine 47Etoposide 44Mycophenolic Acid 41Filgrastim 40Whole-Body Irradiation 37Tacrolimus 36Melphalan 35Bortezomib 34Methotrexate 33Cyclosporine 33Busulfan 31Radiotherapy 30Vincristine 28Doxorubicin 27Dexamethasone 27Carmustine 25Antilymphocyte Serum 25Lenalidomide 23Bendamustine Hydrochloride 23ibrutinib 22Granulocyte Colony-Stimulating Factor 20obinutuzumab 18fludarabine 18acalabrutinib 18Prednisone 18venetoclax 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Mantle-Cell × TQ-B3525 × Clear all
NCT04398953 2020-09-11

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡